RIG-I activation induces the release of extracellular vesicles with antitumor activity

ABSTRACT Activation of the innate immune receptor retinoic acid-inducible gene I (RIG-I) by its specific ligand 5′-triphosphate-RNA (3pRNA) triggers antitumor immunity predominantly via NK cell activation and direct apoptosis induction in tumor cells. However, how NK cells are mobilized to attack the tumor cells remains elusive. Here, we show that RIG-I activation induced the secretion of extracellular vesicles (EVs) from melanoma cells, which by themselves revealed antitumor activity in vitro and in vivo. RIG-I-induced EVs from melanoma cells exhibited an increased expression of the NKp30-ligand (BAG6, BAT3) on their surface triggering NK cell-mediated lysis of melanoma cells via activation of the cytotoxicity NK cell-receptor NKp30. Moreover, systemic administration of RIG-I-induced melanoma-EVs showed a potent antitumor activity in a melanoma mouse model in vivo. In conclusion, our data establish a new RIG-I-dependent pathway leading to NK cell-mediated tumor cell killing.

[1]  D. Schadendorf,et al.  Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. , 2016, Cancer research.

[2]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[3]  Olivier Lantz,et al.  Dendritic cell-derived exosomes as maintenance immunotherapy after first line chemotherapy in NSCLC , 2015, Oncoimmunology.

[4]  Vidar Skaug,et al.  Association of the FAM46A Gene VNTRs and BAG6 rs3117582 SNP with Non Small Cell Lung Cancer (NSCLC) in Croatian and Norwegian Populations , 2015, PloS one.

[5]  M. Büchler,et al.  Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice , 2015, International journal of cancer.

[6]  H. Ishwaran,et al.  Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways , 2014, Cell.

[7]  M. Zöller,et al.  Outsmart tumor exosomes to steal the cancer initiating cell its niche. , 2014, Seminars in cancer biology.

[8]  S. Endres,et al.  RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8+ T cells , 2014, Cell Death and Differentiation.

[9]  J. Koch,et al.  BAG-6, a jack of all trades in health and disease , 2014, Cellular and Molecular Life Sciences.

[10]  C. Coch,et al.  Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity , 2014, Front. Immunol..

[11]  P. Robbins,et al.  Regulation of immune responses by extracellular vesicles , 2014, Nature Reviews Immunology.

[12]  J. Koch,et al.  A Soluble Fragment of the Tumor Antigen BCL2-associated Athanogene 6 (BAG-6) Is Essential and Sufficient for Inhibition of NKp30 Receptor-dependent Cytotoxicity of Natural Killer Cells* , 2013, The Journal of Biological Chemistry.

[13]  J. Mertens,et al.  Targeting the Cytosolic Innate Immune Receptors RIG‐I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma , 2013, Stem cells.

[14]  M. Hallek,et al.  Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. , 2013, Blood.

[15]  C. Coch,et al.  Exosomes as nucleic acid nanocarriers. , 2013, Advanced drug delivery reviews.

[16]  J. Lötvall,et al.  Distinct RNA profiles in subpopulations of extracellular vesicles: apoptotic bodies, microvesicles and exosomes , 2013, Journal of extracellular vesicles.

[17]  F. Chisari,et al.  Short-range exosomal transfer of viral RNA from infected cells to plasmacytoid dendritic cells triggers innate immunity. , 2012, Cell host & microbe.

[18]  J. Landsberg,et al.  Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation , 2012, Nature.

[19]  S. Rai,et al.  Identifying mRNA, MicroRNA and Protein Profiles of Melanoma Exosomes , 2012, PloS one.

[20]  S. Raimondo,et al.  Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis , 2012, PloS one.

[21]  Qiao Li,et al.  Tumor cell-derived exosomes: a message in a bottle. , 2012, Biochimica et biophysica acta.

[22]  A. Izzo,et al.  BAT3 Regulates Mycobacterium tuberculosis Protein ESAT-6-Mediated Apoptosis of Macrophages , 2012, PloS one.

[23]  Gema Moreno-Bueno,et al.  Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET , 2012, Nature Medicine.

[24]  Li-hong Lv,et al.  Anticancer Drugs Cause Release of Exosomes with Heat Shock Proteins from Human Hepatocellular Carcinoma Cells That Elicit Effective Natural Killer Cell Antitumor Responses in Vitro* , 2012, The Journal of Biological Chemistry.

[25]  Hamid Cheshmi Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers , 2011 .

[26]  S. Wickline,et al.  Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. , 2011, Cancer research.

[27]  György Nagy,et al.  Cellular and Molecular Life Sciences REVIEW Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles , 2022 .

[28]  D. Lyden,et al.  The secreted factors responsible for pre-metastatic niche formation: old sayings and new thoughts. , 2011, Seminars in cancer biology.

[29]  H. Shime,et al.  Natural Killer Cell Activation Secondary to Innate Pattern Sensing , 2011, Journal of Innate Immunity.

[30]  Taoyong Chen,et al.  Chemokine-Containing Exosomes Are Released from Heat-Stressed Tumor Cells via Lipid Raft-Dependent Pathway and Act as Efficient Tumor Vaccine , 2011, The Journal of Immunology.

[31]  Taoyong Chen,et al.  Stress for maintaining memory: HSP70 as a mobile messenger for innate and adaptive immunity , 2010, European journal of immunology.

[32]  L. Zitvogel,et al.  Dendritic cell-derived exosomes for cancer immunotherapy: what's next? , 2010, Cancer research.

[33]  Bai-Cheng He,et al.  Exosomes derived from IL-12-anchored renal cancer cells increase induction of specific antitumor response in vitro: a novel vaccine for renal cell carcinoma. , 2009, International journal of oncology.

[34]  C. Berking,et al.  Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferon-independent apoptosis in human melanoma cells. , 2009, The Journal of clinical investigation.

[35]  C. Théry,et al.  Membrane vesicles as conveyors of immune responses , 2009, Nature Reviews Immunology.

[36]  Osamu Takeuchi,et al.  Recognition of 5' triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. , 2009, Immunity.

[37]  Eric Vivier,et al.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans , 2009, The Journal of experimental medicine.

[38]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[39]  Svetlana Shulga Morskaya,et al.  5′-triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma , 2008, Nature Medicine.

[40]  A. Engert,et al.  Dendritic Cells Release HLA-B-Associated Transcript-3 Positive Exosomes to Regulate Natural Killer Function , 2008, PloS one.

[41]  G. Hartmann,et al.  Accessing the therapeutic potential of immunostimulatory nucleic acids. , 2008, Current opinion in immunology.

[42]  M. Mason,et al.  Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression1 , 2008, The Journal of Immunology.

[43]  Michael Hallek,et al.  Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. , 2007, Immunity.

[44]  H. Bickeböller,et al.  The Heat Shock Protein HSP70 Promotes Mouse NK Cell Activity against Tumors That Express Inducible NKG2D Ligands1 , 2007, The Journal of Immunology.

[45]  L. Hawthorn,et al.  Identifying candidate colon cancer tumor suppressor genes using inhibition of nonsense-mediated mRNA decay in colon cancer cells , 2007, Oncogene.

[46]  G. Parmiani,et al.  Tumor-released microvesicles as vehicles of immunosuppression. , 2007, Cancer research.

[47]  Gunther Hartmann,et al.  5'-Triphosphate RNA Is the Ligand for RIG-I , 2006, Science.

[48]  A. Villa,et al.  Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes. , 2006, Cancer research.

[49]  William E. Grizzle,et al.  Murine Mammary Carcinoma Exosomes Promote Tumor Growth by Suppression of NK Cell Function1 , 2006, The Journal of Immunology.

[50]  J. Chin,et al.  Tumor exosomes expressing Fas ligand mediate CD8+ T-cell apoptosis , 2005 .

[51]  M. Febbraio,et al.  Exosome-dependent Trafficking of HSP70 , 2005, Journal of Biological Chemistry.

[52]  C. Gross,et al.  Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. , 2005, Cancer research.

[53]  P. Selby,et al.  Proteomic analysis of melanoma‐derived exosomes by two‐dimensional polyacrylamide gel electrophoresis and mass spectrometry , 2004, Proteomics.

[54]  T. Ichim,et al.  Tumor exosomes expressing fas ligand mediate CD8+ T cell apoptosis , 2004, Annals of Surgical Oncology.

[55]  D. Purdie,et al.  Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine , 2003, Cancer Immunology, Immunotherapy.

[56]  R. Morimoto,et al.  Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper , 2001, The EMBO journal.

[57]  G. Parmiani,et al.  Tumour-released exosomes and their implications in cancer immunity , 2008, Cell Death and Differentiation.